E. Jay Wilusz
Patent Attorney, Attorney at Law
Massachusetts
NJ, WA, Patent Bar
"Easy communication, Very Knowledgeable Attorney!"
About
clients
upcounsel
experience
Representative Clients
Practice Areas
Client Reviews
"I am pleased with the high quality of Jay's work."
"Easy communication, Very Knowledgeable Attorney!"
"Good experience. Will continue to use his service."
"Would highly recommend Jay and will use him again if the circumstances call for it. Not only does he have a lot of knowledge and experience, but is also pleasant and easy to talk to."
"I would hire Jay again."
"I would hire Jay again."
Work History
EJW Pharma Strategy LLC
Principal and Founder
Jul 2012 - Present
• Advise pharma companies on business development, IP, regulatory, and licensing strategies.
• Design and implement IP, legal, marketing, business development and regulatory opportunities for Life Science products.
• Completed license deal of multiple products for 400 MM USD for a top 5 global Life Science company.
• Implement new development and marketing plans for Sanofi TB drug, Priftin®.
Sanofi
US Life Cycle Management Oncology and Multiple Sclerosis Franchises Lead
Oct 2010 - Jun 2012
• Led teams of multi-functional experts to develop exclusivity for Aubagio®, Lemtrada®, Jevtana®, and Elitek®, via indications, drug delivery, drug repurposing and adherence projects.
• Appraised biotechnology and asset values for the acquisition of Genzyme.
• Implemented biotech strategy and due diligence for US and EU product development and marketing.
• Negotiated licensing agreement terms.
Novartis Pharmaceuticals
Vice President, Pharma Regions Counsel, No. & So. America & Japan, Pharma IP Dept.
Jun 2001 - Aug 2010
• Obtained product patent protection, asset licenses, IP rights and rendered opinions for products with sales of 15+ Billion USD.
• Successful litigation outcome for products worth 1+ Billion USD.
• Negotiated IP protection and exclusivity with government entities and organizations in US, CA, LatAm and Japan.
• Implemented strategy, initiatives, and financial controls for 25 member IP staff.